VivoSeq
Dermatology

Hypertrophic Scar

1

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Hypertrophic Scar is an early-stage landscape with 1 program across 3 companies. The most active players are Shanghai Ark Biopharmaceutical Co., Ltd., Eli Lilly, Olix Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

40/100

Attrition Rate

60/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Ark Biopharmaceutical Co., Ltd.

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

PreclinicalO

Olix Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

AK3280

Shanghai Ark Biopharmaceutical Co., Ltd.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Terminated2 · 40%
Withdrawn1 · 20%

Clinical Trials

Trial Activity

Intron A for the Treatment of Hypertrophic Scar
Withdrawn·UUniversity of Alberta·Phase 3·NCT00686478
Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery
Completed·OOlix Pharmaceuticals, Inc.·Phase 2·NCT04877756·22 enrolled
the Hypertrophic Scar Prevention of BMT101.
Terminated·HHugel·Phase 2·NCT04012099·20 enrolled
Hypertrophic Scar Prevention by Novel Topical Gel Application
Terminated·MMayo Clinic·Phase 1/2·NCT03403621·6 enrolled
A Randomized, Double-blind, Placebo Self-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preventive Efficacy of AK3280 Cream After Cicatrectomy in Patients With Hypertrophic Scar in China.
Completed·SShanghai Ark Biopharmaceutical Co., Ltd.·Preclinical·NCT05434897·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)